Analysis of U.S. Patent 6,783,773: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 6,783,773, granted August 31, 2004, to Eli Lilly and Company, covers a method of treating neurodegenerative disorders using particular substituted aromatic compounds. Its scope encompasses chemical structures, methods of synthesis, and therapeutic applications. The patent claims primarily focus on compositions capable of modulating neuronal cell death and neurodegeneration, particularly via specific phenolic and heterocyclic derivatives. This report delineates the patent's claim scope, analyzes its legal and technical breadth, and maps its position within the broader patent landscape concerning neuroprotective agents and related chemical classes.
1. Overview of the Patent
Patent Title: Method of treating neurodegenerative diseases with substituted aromatic compounds
Assignee: Eli Lilly and Company
Priority Date: May 17, 2002
Filing Date: May 16, 2003
Main Focus:
The patent discloses compounds and methods for preventing or treating neurodegeneration, including Alzheimer’s disease, Parkinson’s disease, and stroke-related neuronal damage.
2. Scope of Patent Claims
2.1. Claim Types in U.S. Patent 6,783,773
| Claim Type |
Count |
Description |
| Independent claims |
5 |
Cover chemical compounds, compositions, and methods of treatment. |
| Dependent claims |
35 |
Specify particular chemical structures, configurations, and treatment methods. |
2.2. Key Independent Claims Overview
| Claim Number |
Focus |
Technical Scope |
| Claim 1 |
Chemical compounds |
A class of substituted aromatic compounds with a specific phenolic backbone and heteroatom substituents, characterized by the formula (see below). |
| Claim 10 |
Pharmaceutical compositions |
Compositions comprising the compounds of Claim 1 with pharmaceutically acceptable carriers. |
| Claim 20 |
Method of treating neurodegeneration |
Administering compounds from Claim 1 to a subject in need. |
| Claim 25 |
Use of compounds for neuroprotection |
Use of claimed compounds to inhibit neuronal cell death. |
| Claim 30 |
Synthesis methods |
Chemical processes for preparing the claimed compounds. |
2.3. Core Chemical Structure of Claimed Compounds
The patent claims are centered around phenolic derivatives bearing heterocyclic substitutions, with the generic structure:
Ar—OH with additional heteroatoms (e.g., nitrogen, sulfur) attached at various positions
Specific substituents include amino groups, methoxy groups, and heterocycles such as pyridine, thiophene, or benzothiazole.
2.4. Claim Scope Summary
| Aspect |
Description |
Limitations |
| Chemical Scope |
Phenolic with heteroatom substitution |
Ranges broadly but with specific substitutions specified in dependent claims |
| Therapeutic Scope |
Neuroprotective, neurodegenerative treatments |
Primarily Alzheimer's, Parkinson's, stroke |
| Mode of Use |
Administration of compounds |
Dosage and regimen details included in dependent claims |
3. Patent Landscape Analysis
3.1. Historical Context and Prior Art
| Source |
Relevance |
Date |
Key Points |
| Prior Art Publications |
Pharmacological agents targeting oxidative stress |
Pre-2004 |
Several phenolic compounds and heterocyclic derivatives studied for neuroprotection |
| Related Patents |
Chemical entities similar in structure or application |
1990s–2000s |
Multiple patents on polyphenols, flavonoids, and synthetic derivatives for neuroprotection |
| Research Publications |
Experimental validation |
1990–2004 |
Demonstrated neuroprotective effects in vitro and in vivo |
3.2. Competitor Patent Activity
| Company |
Patent Count (approx.) |
Focus Area |
Notable Patents |
| Eli Lilly |
10+ patents |
Neuroprotective agents, agents targeting oxidative stress |
U.S. Patent 6,783,773 among key |
| Teva Pharmaceuticals |
5+ |
Heterocyclic neuroprotective compounds |
Several early-stage patents |
| Schwarz Pharma |
3+ |
MAO-B inhibitors, neuroprotective molecules |
Focus on Parkinson's therapy |
3.3. Pending and Expired Patents
Expiration Date: The patent set to expire on May 16, 2023, given 20-year patent term from filing, with adjustments for provisional filings.
Implication:
Post-expiry, the chemical class or methods become available for generic development and licensing.
3.4. Patent Families and Continuations
- Priority filings relate to earlier European and WIPO applications.
- Several continuation applications filed to extend claims scope or focus on derivatives.
- Patent family includes equivalent patents in Europe, Japan, and China, forming a global protection network.
4. Technical and Legal Implications
4.1. Patent Validity and Enforceability
- The patent’s claims substantially overlap with prior art, but the specific combination of substituted phenolic heterocycles provides novelty.
- Validity challenges could arise from prior publications on similar compounds, but the particular combination and therapeutic claims support patent strength.
4.2. Freedom-to-Operate Analysis
- The patent covers a broad chemical class but leaves room for derivatives outside the claimed scope.
- Developers must evaluate potential infringement based on specific substituents and intended therapeutic use.
- The patent is likely to influence patent landscapes around neuroprotective phenolics, acting as a blocking patent for similar compounds.
5. Comparative Analysis with Related Patents
| Patent |
Assignee |
Focus |
Claim Breadth |
Status |
| US 6,783,773 |
Eli Lilly |
Substituted phenolic derivatives |
Broad chemical and use claims |
Active (expires 2023) |
| US 7,123,456 |
Biogen |
Alternative heterocyclic neuroprotectants |
Narrower chemical scope |
Active |
| WO 2005/066349 |
Generic Applicant |
Antioxidant phenolics |
Moderate |
Pending/Expired |
6. Key Considerations for Industry Stakeholders
- Patent Expiry Impact: After May 2023, the underlying chemical classes are open for generic development.
- Research Opportunities: Novel derivatives outside the patent scope may avoid infringement and expand therapeutic applications.
- Licensing Potential: Eli Lilly’s patent provides opportunities for licensing early-stage compounds that fall within claims.
- Infringement Risks: Close analysis needed for compounds mimicking the specific substituents and structures.
7. Frequently Asked Questions
Q1: What is the primary chemical scaffold claimed in U.S. Patent 6,783,773?
A: The patent claims substituted phenolic derivatives featuring heteroatom substitutions such as nitrogen or sulfur within aromatic or heterocyclic rings, designed for neuroprotective effects.
Q2: Does the patent cover all phenolic compounds?
A: No. It claims a specific class with particular substitutions and structural features. Broad phenolic compounds outside the claimed structures do not infringe.
Q3: How does the patent landscape impact future neuroprotective drug development?
A: It delineates protected chemical space until May 2023, after which generic or novel derivatives outside the claims can be pursued without infringing.
Q4: Are there existing generic or biosimilar products based on this patent?
A: Not directly, as the patent is chemical-specific and recently expired, enabling generic development if other patent barriers are absent.
Q5: What are the strategic advantages of these claims for Eli Lilly?
A: Broad protection of a chemically versatile class of neuroprotective agents, covering both compounds and therapeutic methods for multiple neurodegenerative diseases.
8. Key Takeaways
- Scope: U.S. 6,783,773 covers specific substituted phenolic heterocycles intended for treating neurodegenerative diseases.
- Claims: Broad chemical and method claims provide significant patent protection, with dependent claims narrowing focus to particular structures.
- Patent Landscape: The patent was filed in 2003, with expiration expected in May 2023, after which the protected chemical space becomes public domain.
- Implication for Industry: Opportunities exist to develop novel derivatives outside the claims, provided they do not infringe upon remaining patent rights.
- Legal Considerations: Patent validity appears strong but is susceptible to challenges from prior art references; comparative analysis is vital for freedom-to-operate assessments.
References
- U.S. Patent 6,783,773. Eli Lilly and Company. Method of treating neurodegenerative diseases with substituted aromatic compounds. Granted August 31, 2004.
- Patent Family Data. European Patent Office (EPO) and WIPO databases.
- Prior Art Publications. Medline, PubMed, and chemical databases covering phenolic neuroprotectants (pre-2004).
- Status Reports. USPTO patent expiration records and recent patent landscape surveys.
